Granted Patent
B2
US 12,458,622 · App. 17/917,022 · Granted Nov 4, 2025
Methods of treatment of coronavirus-induced inflammation conditions
Inventors:
David R. Elmaleh (Newton, MA); Ana Griciuc (Arlington, MA); Ghazaleh Sadri-Vakili (Watertown, MA); Sabrina Paganoni (Boston, MA); Rudolph E. Tanzi (Milton, MA)
Assignee:
The General Hospital Corporation
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to a method of treating one or more inflammation conditions induced by a coronavirus infection in a subject in need thereof, comprising administering a pharmaceutical composition comprising a compound of Formula I or Formula II: wherein R 1 is halogen, OH, or —OC(O)C 1-5 alkyl R 2 and R 3 are each independently selected from CO 2 R 4 and CH 2 OR 5 ; R 4 is Li, Na, K, H, C 1-5 alkyl, or —CH 2 CO(C 1-5 alkyl); and R 5 is H or —C(O)(C 1-5 alkyl), or a pharmaceutically acceptable salt thereof.
Claims (27)
1. A method of treating one or more inflammation condition induced by a coronavirus infection, comprising administering a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprises a pharmaceutically acceptable excipient and a compound having the following chemical structure:
or a pharmaceutically acceptable salt thereof; and
wherein the one or more inflammation condition is selected from acute respiratory distress syndrome (ARDS), pneumonia, myocarditis, haemophagocytic lymphohistiocytosis (sHLH), kidney failure, septic shock, and sepsis.
2. The method of claim 1 , wherein the compound of Formula I is
3. The method of claim 1 , wherein the compound is present in the pharmaceutical composition at a concentration from about 0.1 mg/mL to about 20 mg/mL.
4. The method of claim 1 , comprising administering the pharmaceutical composition by intravenous infusion, by intravenous injection, by subcutaneous injection, by intramuscular injection, by intraperitoneal injection, orally, sublingually, buccally, or by inhalation.
5. The method of claim 1 , wherein the coronavirus is selected from SARS-CoV, MERS-CoV, HCoV, HKU1, and SARS-CoV-2.
6. The method of claim 5 , wherein the coronavirus is SARS-CoV-2.
7. The method of claim 1 , wherein the one or more inflammation condition is acute respiratory distress syndrome (ARDS).
8. The method of claim 1 , further comprising administering one or more antiviral agent.
9. The method of claim 8 , wherein the one or more antiviral agents is selected from remdesivir (RDV), tilorone, favipiravir, IFNα, IFNβ, IFNγ, peginterferon-α, peginterferon-β, ribavirin, lopinavir/ritonavir, camostat mesylate, TAK888, abacavir, acyclovir, adefovir, amantadine, rintatolimod (Ampligen), amprenavir, umifenovir (Arbidol), and atazanavir.
10. The method of claim 1 , further comprising administering one or more antimicrobial agent.
11. The method of claim 10 , wherein the one or more antimicrobial agents is selected from penicillin, ampicillin, sulbactam, piperacillin, tazobactam, a macrolide, an aminoglycoside, a cephalosporin, and a glycopeptide.
12. The method of claim 1 , further comprising administering an immune suppressant agent.
13. The method of claim 12 , wherein the immune suppressant agent is selected from tocilizumab, siltuximab, infliximab, abatacept, leronlimab, anakinra, and a JAK inhibitor.
14. The method of claim 1 , further comprising administering a hyperimmune globulin, wherein the hyperimmune globulin is isolated from patients recovered from the coronavirus infection.
15. The method of claim 1 , further comprising administering an angiotensin II type 1 receptor blocker (ARB).
16. The method of claim 15 , wherein the ARB is selected from valsartan, telmisartan, losartan, irbesartan, azilsartan, and olmesartan.
17. The method of claim 1 , further comprising administering a mast cell stabilizer.
18. The method of claim 17 , wherein the mast cell stabilizer is selected from nedocromil, ketotifen, quercetin, omalizumab, olopatadine, azelastine, mepolizumab, methyl xanthines, and β2-adrenergic agonists.
19. The method of claim 1 , wherein the subject has SARS-CoV-2 infection, which has been confirmed by reverse-transcription polymerase chain reaction (RT-PCR) from a respiratory tract or blood specimen.
20. The method of claim 1 , wherein the one or more inflammation condition is pneumonia.
21. The method of claim 1 , wherein the one or more inflammation condition is myocarditis.
22. The method of claim 1 , wherein the one or more inflammation condition is haemophagocytic lymphohistiocytosis (sHLH).
23. The method of claim 1 , wherein the one or more inflammation condition is kidney failure.
24. The method of claim 1 , wherein the one or more inflammation condition is septic shock.
25. The method of claim 1 , wherein the one or more inflammation condition is sepsis.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 6, 2022
From: ELMALEH, DAVID R.; GRICIUC, ANA; SADRI-VAKILI, GHAZALEH; PAGANONI, SABRINA; TANZI, RUDOLPH E.
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 061995/0269 →
Continuity (2)
Provisional Application
63005720
· Apr 6, 2020
References Cited (400)
US 3419578A
· Fitzmaurice et al.
· 1968
[cited by applicant]
US 3634582A
· Hartley et al.
· 1972
[cited by applicant]
US 3686412A
· Fitzmaurice et al.
· 1972
[cited by applicant]
US 3957965A
· Hartley et al.
· 1976
[cited by applicant]
US 4120285A
· Nugent
· 1978
[cited by applicant]
US 4405598A
· Brown
· 1983
[cited by applicant]
US 4405735A
· Wiezer et al.
· 1983
[cited by applicant]
US 4429545A
· Steinberg
· 1984
[cited by applicant]
US 4481206A
· Spiegel et al.
· 1984
[cited by applicant]
US 4996296A
· Pecht et al.
· 1991
[cited by applicant]
US 5376386A
· Ganderton et al.
· 1994
[cited by applicant]
US 5567720A
· Averback
· 1996
[cited by applicant]
US 5594142A
· Gaa et al.
· 1997
[cited by applicant]
US 5655523A
· Hodson et al.
· 1997
[cited by applicant]
US 5830920A
· Chucholowski et al.
· 1998
[cited by applicant]
US 5904937A
· Augello et al.
· 1999
[cited by applicant]
US 6168776B1
· Klunk et al.
· 2001
[cited by applicant]
US 6197963B1
· Hirschmann et al.
· 2001
[cited by applicant]
US 6309623B1
· Weers et al.
· 2001
[cited by applicant]
US 6696039B2
· Kung et al.
· 2004
[cited by applicant]
US 6911466B2
· Koo et al.
· 2005
[cited by applicant]
US 6946116B2
· Kung et al.
· 2005
[cited by applicant]
US 6972127B2
· Schenk
· 2005
[cited by applicant]
US 7160559B1
· McGee et al.
· 2007
[cited by applicant]
US 7186401B2
· Keller et al.
· 2007
[cited by applicant]
US 7858803B2
· Elmaleh et al.
· 2010
[cited by applicant]
US 8381454B1
· Robinson
· 2013
[cited by applicant]
US 8613920B2
· Lieberburg et al.
· 2013
[cited by applicant]
US 8617517B2
· Elmaleh et al.
· 2013
[cited by applicant]
US 8765742B2
· Hilifiker et al.
· 2014
[cited by applicant]
US 9283230B2
· Clunas et al.
· 2016
[cited by applicant]
US 9855276B2
· Elmaleh
· 2018
[cited by applicant]
US 9861608B2
· Elmaleh et al.
· 2018
[cited by applicant]
US 9913847B2
· Elmaleh
· 2018
[cited by applicant]
US 9918992B2
· Elmaleh
· 2018
[cited by applicant]
US 9925282B2
· Elmaleh et al.
· 2018
[cited by applicant]
US 9968618B1
· Elmaleh
· 2018
[cited by applicant]
US 20020009491A1
· Rothbard et al.
· 2002
[cited by applicant]
US 20020016359A1
· Hellberg et al.
· 2002
[cited by applicant]
US 20020091100A1
· Lezdey et al.
· 2002
[cited by applicant]
US 20020107173A1
· Friedhoff et al.
· 2002
[cited by applicant]
US 20040223918A1
· Pham et al.
· 2004
[cited by applicant]
US 20040259952A1
· Abbas et al.
· 2004
[cited by applicant]
US 20060142241A1
· Yoo
· 2006
[cited by applicant]
US 20060159629A1
· Tarara et al.
· 2006
[cited by applicant]
US 20060240007A1
· Sanders
· 2006
[cited by applicant]
US 20060276455A1
· Lindsberg et al.
· 2006
[cited by applicant]
US 20070015813A1
· Carter et al.
· 2007
[cited by applicant]
US 20070053843A1
· Dawson et al.
· 2007
[cited by applicant]
US 20070071690A1
· Mueller-Walz et al.
· 2007
[cited by applicant]
US 20070086981A1
· Meijer et al.
· 2007
[cited by applicant]
US 20070093457A1
· Arber et al.
· 2007
[cited by applicant]
US 20070178166A1
· Bernstein et al.
· 2007
[cited by applicant]
US 20070293538A1
· Hobden
· 2007
[cited by applicant]
US 20080021085A1
· Koo et al.
· 2008
[cited by applicant]
US 20090110679A1
· Li et al.
· 2009
[cited by applicant]
US 20090155256A1
· Black et al.
· 2009
[cited by applicant]
US 20100113613A1
· McLaurin et al.
· 2010
[cited by applicant]
US 20100143251A1
· Tamagnan et al.
· 2010
[cited by applicant]
US 20100173960A1
· Cruz et al.
· 2010
[cited by applicant]
US 20100236550A1
· Zeng et al.
· 2010
[cited by applicant]
US 20110129530A1
· Venkatesh et al.
· 2011
[cited by applicant]
US 20110262442A1
· Hamilton et al.
· 2011
[cited by applicant]
US 20120082727A1
· Cocconi et al.
· 2012
[cited by applicant]
US 20120121656A1
· Watson et al.
· 2012
[cited by applicant]
US 20120134929A1
· McGrath et al.
· 2012
[cited by applicant]
US 20120165366A1
· Ibrahim et al.
· 2012
[cited by applicant]
US 20120175082A1
· Kmetovicz et al.
· 2012
[cited by applicant]
US 20120308613A1
· Staniforth et al.
· 2012
[cited by applicant]
US 20150224077A1
· Gerhart et al.
· 2015
[cited by applicant]
US 20150224078A1
· Gerhart et al.
· 2015
[cited by applicant]
US 20150274680A1
· Ueda et al.
· 2015
[cited by applicant]
US 20160158150A1
· Morton et al.
· 2016
[cited by applicant]
US 20160166534A1
· Elmaleh
· 2016
[cited by applicant]
US 20160310503A1
· Elmaleh
· 2016
[cited by applicant]
US 20180344682A1
· Elmaleh
· 2018
[cited by applicant]
US 20200338040A1
· Elmaleh
· 2020
[cited by applicant]
US 20200383908A1
· Elmaleh
· 2020
[cited by applicant]
US 20210023010A1
· Elmaleh et al.
· 2021
[cited by applicant]
US 20210059977A1
· Elmaleh
· 2021
[cited by applicant]
US 20220125753A1
· Elmaleh
· 2022
[cited by applicant]
US 20220193087A1
· Elmaleh
· 2022
[cited by applicant]
US 20220218652A1
· Elmaleh et al.
· 2022
[cited by applicant]
US 20230226017A1
· Elmaleh
· 2023
[cited by applicant]
US 20230248646A1
· Elmaleh
· 2023
[cited by applicant]
US 20230248650A1
· Elmaleh et al.
· 2023
[cited by applicant]
US 20240082207A1
· Elmaleh
· 2024
[cited by applicant]
CA 2408793A1
· 2001
[cited by applicant]
CN 101754746A
· 2010
[cited by applicant]
CN 101848733A
· 2010
[cited by applicant]
CN 103347500A
· 2013
[cited by applicant]
CN 105377037A
· 2016
[cited by applicant]
CN 108164409A
· 2018
[cited by applicant]
CN 108403708A
· 2018
[cited by applicant]
DE 1543579
· 2005
[cited by applicant]
EP 1632242A2
· 2006
[cited by applicant]
EP 2322163A1
· 2011
[cited by applicant]
EP 2377860A1
· 2011
[cited by applicant]
EP 2391618A2
· 2011
[cited by applicant]
EP 2890788A1
· 2015
[cited by applicant]
EP 2911664B1
· 2019
[cited by applicant]
GB 1144906A
· 1969
[cited by applicant]
GB 1257162A
· 1971
[cited by applicant]
JP S56043448B1
· 1981
[cited by applicant]
JP H04505006A
· 1992
[cited by applicant]
JP 2000503866A
· 2000
[cited by applicant]
JP 2001151673A
· 2001
[cited by applicant]
JP 2001517691A
· 2001
[cited by applicant]
JP 2002524107A
· 2002
[cited by applicant]
JP 2003525842A
· 2003
[cited by applicant]
JP 2005510535A
· 2005
[cited by applicant]
JP 2005232171A
· 2005
[cited by applicant]
JP 2005532091A
· 2005
[cited by applicant]
JP 2007534693A
· 2007
[cited by applicant]
JP 2009536918A
· 2009
[cited by applicant]
JP 2010510254A
· 2010
[cited by applicant]
JP 2012515712A
· 2012
[cited by applicant]
JP 2012516356A
· 2012
[cited by applicant]
WO WO1987001115A1
· 1987
[cited by applicant]
WO WO9009789A2
· 1990
[cited by applicant]
WO WO1997026934A2
· 1997
[cited by applicant]
WO WO9834596A2
· 1998
[cited by applicant]
WO WO1999016422A1
· 1999
[cited by applicant]
WO WO1999064095A2
· 1999
[cited by applicant]
WO WO0228820A1
· 2002
[cited by applicant]
WO WO03045331A2
· 2003
[cited by applicant]
WO WO2004071532A1
· 2004
[cited by applicant]
WO WO2005063732A1
· 2005
[cited by applicant]
WO WO2005104712A2
· 2005
[cited by applicant]
WO WO2006056492A1
· 2006
[cited by applicant]
WO WO2007094718A1
· 2007
[cited by applicant]
WO WO2007102059A1
· 2007
[cited by applicant]
WO WO2008013799A2
· 2008
[cited by applicant]
WO WO2008061373A1
· 2008
[cited by applicant]
WO WO2008128981A1
· 2008
[cited by applicant]
WO WO2008131298A2
· 2008
[cited by applicant]
WO WO2009010770A2
· 2009
[cited by applicant]
WO WO2009133128A1
· 2009
[cited by applicant]
WO WO2010084767A1
· 2010
[cited by applicant]
WO WO2010088455A2
· 2010
[cited by applicant]
WO WO2011136754A1
· 2011
[cited by applicant]
WO WO2013148366A1
· 2013
[cited by applicant]
WO WO2014066318A1
· 2014
[cited by applicant]
WO WO2015002703A1
· 2015
[cited by applicant]
WO WO2015061397A1
· 2015
[cited by applicant]
WO WO2016081466A1
· 2016
[cited by applicant]
WO WO2016196401A1
· 2016
[cited by applicant]
WO WO2017027387A1
· 2017
[cited by applicant]
WO WO2017027402A1
· 2017
[cited by applicant]
WO WO2017072335A1
· 2017
[cited by applicant]
WO WO2017087962A1
· 2017
[cited by applicant]
WO WO2017091644A1
· 2017
[cited by applicant]
WO WO2017162884A1
· 2017
[cited by applicant]
WO WO2018045217A1
· 2018
[cited by applicant]
WO WO2018048989A1
· 2018
[cited by applicant]
WO WO2019199776A1
· 2019
[cited by applicant]
WO WO2020010049A1
· 2020
[cited by applicant]
WO WO2020051322A1
· 2020
[cited by applicant]
WO WO2020123449A1
· 2020
[cited by applicant]
WO WO2021207060A1
· 2021
[cited by applicant]
WO WO2021248022A1
· 2021
[cited by applicant]
WO WO2022146914A1
· 2022
[cited by applicant]
Anonymous: “Facts about variant Creutzfeldt-Jakob disease”, European Centre for Disease Prevention and Control, Jun. 26, 2017 (Jun. 26, 2017), pp. 1-10, XP093093988, European Centre for Disease Prevention and Control we…
[cited by applicant]
Brazier et al., “Pharmacokinetics of cromolyn and ibuprofen in healthy elderly volunteers”, Clinical drug investigation 37: 1025-1034 (2017).
[cited by applicant]
Hofman et al., “Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study,” Lancet 349: pp. 151-154 (1997).
[cited by applicant]
Manuelidis et al., “Transmissible encephalopathy agents,” Virulence 1.2 (2010): 101-104.
[cited by applicant]
Prins et al., “Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future”, Alzheimer's research & therapy 5.6: 1-6 (2013).
[cited by applicant]
Tsivgoulis et al., “Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke,” Journal of Stroke, 20.2 (2018): 145-166.
[cited by applicant]
Yoshimi et al., “Importance of Hydrolysis of Amino Acid Moiety in Water-Soluble Prodrugs of Disodium Cromoglycate for Increased Oral Bioavailability,” Journal of Pharmacobio-Dynamics 15.7 (1992): 339-345.
[cited by applicant]
Abraham et al., “Mast cell-orchestrated immunity to pathogens,” Nat Rev Immunol, 10: 440-452 (2010).
[cited by applicant]
Aisen et al., “Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial,” JAMA, 289(21):2819-2826 (2003).
[cited by applicant]
Akiyama et al., “Inflammation and Alzheimer's Disease,” Neurobiol Aging, 21(3):383-421 (2000).
[cited by applicant]
Alafuzoff et al., “Lower counts of astroglia and activated microglia in patients with Alzheimer's disease with regular use of non-steroidal anti-inflammatory drugs,” J Alzheimers Dis, 2(1):37-46 (2000).
[cited by applicant]
Albert et al., “Effects of age on the clinical pharmacokinetics of ibuprofen,” Am J Med, 77(1, Part 1):47-50 (1984).
[cited by applicant]
Albert et al., “Pharmacokinetics of ibuprofen,” Am J Med, 77(1A):40-46 (1984).
[cited by applicant]
Aloisi F. “Immune function of microglia”.
[cited by applicant]
Andreasen et al. “Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample,” Neurology. (1999) 53: 1488-94 (19 pages).
[cited by applicant]
Arnáiz et al., “Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease,” Acta Neurol Scand Suppl. (2003) 179: 34-41.
[cited by applicant]
Aswania et al., “Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion,” J Clin Pharmacol, 47:613-618 (1999).
[cited by applicant]
Baig et al., “Use of Peptides for the Management of Alzheimer's Disease: Diagnosis and Inhibition,” Frontiers in Aging Neuroscience, 10: 1-6 (2018).
[cited by applicant]
Banati, R. B. et al., “Cytotoxicity of microglia”.
[cited by applicant]
Bannwarth et al., “Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid.,” Br J Clin Pharmacol, 40(3):266-269 (1995).
[cited by applicant]
Barone, F.C. et al., “Tumor necrosis factor-α: a mediator of focal ischemic brain injury”. Stroke (1997) 28, 1233-1244.
[cited by applicant]
Basek et al., “Efficacy of an Isotonic Small Droplet Size Nebulized DSCG on Asthma Control in Children,” Acta Paediatrica, 99(Suppl 462):115 (2010).
[cited by applicant]
Beach et al., “Cromolyn sodium toxicity studies in primates,” Toxicol Appl Pharmacol, 57(3):367-400 (1981).
[cited by applicant]
Beigel JH, et al. “Remdesivir for the treatment of Covid-19—preliminary report,” The New England Journal of Medicine: 1-12 (2020).
[cited by applicant]
Berge et al., “Pharmaceutical salts,” J Pharm Sci, 66(1):1-19 (1977).
[cited by applicant]
Blennow K., “Biomarkers in Alzheimer's disease drug development,” Nat Med. (2010) 16: 1218-22.
[cited by applicant]
Bodor et al., “Improved delivery through biological membranes VII. Dermal delivery of cromoglycic acid (cromolyn) via its prodrugs,” International Journal of Pharmaceutics, 7(1):63- .75 (1980).
[cited by applicant]
Bona, E. et al., “Chemokine and inflammatory cell response to hypoxia-ischemia in immature rats”.
[cited by applicant]
Bot et al., “Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice,” Circulation, 115(19):2516-2525 (2007).
[cited by applicant]
Breitner et al., “Extended results of the Alzheimer's disease anti-inflammatory prevention trial,” Alzheimers Dement, 7(4):402-411 (2011).
[cited by applicant]
Breitner, “Alzheimer disease: The changing view,” Annals Neurol, 49(3):418-419 (2001).
[cited by applicant]
Broe et al., “Anti-inflammatory drugs protect against Alzheimer disease at low doses,” Arch Neurol, 57:1586-1591 (2000).
[cited by applicant]
Buchhave et al., “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia,” Arch Gen Psychiatry. (2012) 69: 98-106.
[cited by applicant]
Bulic et al., “Tau protein and tau aggregation inhibitors,” Neuropharmacology, 59: 276-289 (2010).
[cited by applicant]
Butovsky et al., “Identification of a unique TGF-β-dependent molecular and functional signature in microglia,” Nat Neurosci, 17(3): 131-143 (2014).
[cited by applicant]
Byron et al., “Selection and Validation of Cascade Impactor Test Methods,” Respiratory Drug Delivery IX, 1: 169-178 (2004).
[cited by applicant]
Bäckman et al., “Multiple Cognitive Deficits During the Transition to Alzheimer's Disease,” Journal of Internal Medicine, (2004) 256(3): 195-204.
[cited by applicant]
Cacabelos, “Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics,” Neuropsychiatric Disease and Treatment 3(3):303-333 (2007).
[cited by applicant]
Cairns et al., “Synthesis and Structure-Activity Relationships of Disodium Cromoglycate and Some Related Compounds,” Journal of Medicinal Chemistry, 15(6):583-589 (1972).
[cited by applicant]
Carlesimo et al., “Memory Deficits in Alzheimer's Patients: A Comprehensive Review,” Neuropsychol Rev. (1992) 3(2): 119-169.
[cited by applicant]
Certificate of Analysis for Lactohale LH 201, Alpha-Lactose Monohydrate EP and USP, Full Release (DFE Pharma); Jan. 18, 2016.
[cited by applicant]
Chen et al., “Current experimental therapy for Alzheimer's Disease,” Curr Neuropharmacol, 5(2): 127-134 (2007).
[cited by applicant]
Cherry et al., “Neuroinflammation and M2 microglia: the good, the bad, and the inflamed,” J Neuroinflammation, 11(98): 1-15 (2014).
[cited by applicant]
Choi et al., “A three-dimensional human neural cell culture model of Alzheimer's disease,” Nature, 515: 274-278 (2014).
[cited by applicant]
Chow et al., “Investigation of Electrostatic Behavior of a Lactose Carrier for Dry Powder Inhalers,” Pharmaceutical Research, 25(12): 2822-2834 (2008).
[cited by applicant]
ClinicalTrials.gov. Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers. Sponsor: AZTherapies, Inc. Identifier: NCT02482324. Retrieved Apr. 9, 2020 from: http://clinicaltrials.gov/ct/show/NCT02482…
[cited by applicant]
ClinicalTrials.gov. Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI). Sponsor: AZTherapies, Inc. Identifier: NCT03202147. Retrieved Feb. 6, 2020, 2…
[cited by applicant]
ClinicalTrials.gov. Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease (COGNITE). Sponsor: AZTherapies, Inc. Identifier: NCT02547818. Retrieved Apr. 9, 2020 from: https://clinic…
[cited by applicant]
ClinicalTrials.gov. Treatment of Acute Stroke With Cromolyn(Single Dose). Sponsor: Wolfson Medical Center. Identifier: NCT01175525. Retrieved Feb. 6, 2020 from: https://clinicaltrials.gov/ct2/show/NCT01175525.
[cited by applicant]
Cole et al., “Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease,” CNS Neurol Disord Drug Targets, 9(2):140-148 (2010).
[cited by applicant]
Conti et al., “Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies,” J Biol Regul Homeost Agents, 34(2): 327-331 (2020).
[cited by applicant]
Cowell, R.M et al., “Hypoxic-ischemic injury induces macrophage inflammatory protein-1 alpha expression in immature rat brain,”
[cited by applicant]
Cox et al., “Disodium Cromoglycate (FPL 670) (‘Intal’*): A Specific Inhibitor of Reaginic Antibody-Antigen Mechanisms,” Nature, 216: 1328-1329 (1967).
[cited by applicant]
Cruz M.P., “Edaravone (Radicava): A novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis,” P&T. (2018) 43(1):25-28.
[cited by applicant]
Cummings, “Alzheimer's Disease,” N Engl J Med, 351(1):56-67 (2004).
[cited by applicant]
Das et al., “Importance of particle size and shape on the tensile strength distribution and de-agglomeration of cohesive powders,” Powder Technology, 249: 297-303 (2013).
[cited by applicant]
Davies, “Clinical pharmacokinetics of ibuprofen. The first 30 years,” Clin Pharmacokinet, 34(2):101-154 (1998).
[cited by applicant]
Deiana et al., “Methylthioninium Chloride Versus Rivastigmine and Their Co-Administration Efficacy in Reversing Scopolamine-Induced Cognitive Deficits in a Pharmacological Mouse Model of Alzheimer's Disease,” Alzheimer'…
[cited by applicant]
Dello Russo et al., “The human microglial HMC3 cell line: where do we stand? A systematic literature review,” J Neuroinflammation, 15: 259 (24 pages) (2018).
[cited by applicant]
Denes, A. et al., “Proliferating resident microglia after focal cerebral ischaemia in mice,”
[cited by applicant]
Desmond, D.W. et al., “Frequency and clinical determinants of dementia after ischemic stroke.”
[cited by applicant]
Dickson et al., “Diffuse Lewy body disease,” Acta Neuropathol (Berl), 75: 8-15 (1987).
[cited by applicant]
Doody et al., “Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial,” Neurology, 72(18):1555-1581 (2009).
[cited by applicant]
Du et al., “Role of Microglia in Neurological Disorders and Their Potentials as a Therapeutic Target,” Mol Neurobiol, 54: 7567-7584 (2017).
[cited by applicant]
Dubbelaar et al., “The Kaleidoscope of Microglial Phenotypes,” Front Immunol, 9: 1753 (2018).
[cited by applicant]
Dunbar et al., “Dispersion and Characterization of Pharmaceutical Dry Powder Aerosols,” Kona, 16:7-45 (1998).
[cited by applicant]
Elmaleh, D. et al., “Evaluation of F-18 Radiolabeled Cromolyn as a Potential Aβ Polymerization Inhibitor and PET Tracer”. Poster at
[cited by applicant]
EPAR (European Public Assessment Report) Seebri Breezhaler: Retrieved online at <http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002430/human_med_001580.jsp&mid=WC0b01ac058001d124>: 6 pages (…
[cited by applicant]
Etminan et al., “Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies,” Brit Med J, 327:128-131 (2003).
[cited by applicant]
European Search Report for EP Application No. 13848340 dated Feb. 11, 2016.
[cited by applicant]
European Search Report for European Application No. 14819448.3 dated Feb. 2, 2017.
[cited by applicant]
Extended European Search Report for EP Application No. 10736439.0 issued Jun. 12, 2012.
[cited by applicant]
Extended European Search Report for EP Application No. 16867341.6 mailed Jun. 13, 2019.
[cited by applicant]
Extended European Search Report for EP Application No. 17934303 mailed Aug. 13, 2021.
[cited by applicant]
Extended European Search Report for EP Application No. 19786110.7 dated Mar. 7, 2022.
[cited by applicant]
Extended European Search Report for EP Application No. 19830061.8 dated Mar. 11, 2022.
[cited by applicant]
Extended European Search Report for EP Application No. 19857627.4 dated Aug. 8, 2022.
[cited by applicant]
Extended European Search Report for EP Application No. 19895399.4 dated Oct. 27, 2022.
[cited by applicant]
Extended European Search Report for EP Application No. EP 16869210 dated Sep. 19, 2019.
[cited by applicant]
Extended European Search Report for EP Application No. EP 17847576 dated Jun. 30, 2020.
[cited by applicant]
Extended European Search Report for EP Application No. EP 17918310 mailed Mar. 12, 2021.
[cited by applicant]
Extended European Search Report for EP Application No. EP 19166810 dated Sep. 23, 2019.
[cited by applicant]
Extended European Search Report for EP Application No. EP 19172666 dated Jan. 10, 2020.
[cited by applicant]
Extended European Search Report, EP 14855211.0, dated May 29, 2017.
[cited by applicant]
Fiala, M. et al., “IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients,”
[cited by applicant]
Findeis et al., “Design and testing of inhibitors of fibril formation,” Methods Enzymol, 309:476-488 (1999).
[cited by applicant]
Findeis et al., “Modified-peptide inhibitors of amyloid B-peptide polymerization,” Biochemistry, 38(21):6791-6800 (1999).
[cited by applicant]
Francesch et al., “Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases,” J Gerontol A Biol Sci Med Sci, 69(S1): S4-9 (2014).
[cited by applicant]
Franzius, D., et al., “Non-specific effects of calcium entry antagonists in mast cells,”
[cited by applicant]
Gadani et al., “IL-4 in the brain: a cytokine to remember,” J Immunol, 189(9): 4213-4219 (2012).
[cited by applicant]
Galimberti et al., “Disease-modifying treatments for Alzheimer's disease,” Ther Adv Neurol Disord, 4(4): 203-216 (2011).
[cited by applicant]
Garmise, “Novel Dry Powder Preparations of Whole Inactivated Influenza Virus for Nasal Vaccination,” Dissertation, University of North Carolina at Chapel Hill (2007).
[cited by applicant]
Garringer et al., “Modeling familial British and Danish dementia”, Brain Struct Funct 214(2-3): 235-244 (2010).
[cited by applicant]
Gasparini et al., “Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action,” J Neurochem, 91(3):521-536 (2004).
[cited by applicant]
Ghasemi. M. and Brown. R.H. Jr. “Genetics of amyotrophic lateral sclerosis,”
[cited by applicant]
Gilani et al., “Influence of Formulation Variables and Inhalation Device On the Deposition Profiles of Cromolyn Sodium Dry Powder Aerosols,” Daru 12(3):123-130 (2004).
[cited by applicant]
Gilead Announces Approval of Veklury (remdesivir) in Japan for Patients With Severe COVID-19. The press release of Gilead Sciences. May 7, 2020. URL: < https://www.gilead.com/news-and-press/press-room/press-releases/202…
[cited by applicant]
Gomperts et al., “Imaging amyloid deposition in Lewy body disease,” Neurology, 71(12): 903-910 (2008).
[cited by applicant]
Gorelick, P. et al., “Vascular Contributions to Cognitive Impairment and Dementia, A Statement for Healthcare Professionals from the American Heart Association/American Stroke Association,”
[cited by applicant]
Gosselin et al., “An environment-dependent transcriptional network specifies human microglia identity,” Science, 356: eaal3222 (2017).
[cited by applicant]
Granucci et al., “Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis,” Sci Rep, 9: 17728 (17 pages) (2019).
[cited by applicant]
Granucci et al., “Inducible IL-2 production by dendritic cells revealed by global gene expression analysis,” Nat Immunol, 2(9): 882-888 (2001).
[cited by applicant]
Greenhalgh et al., “Immune cell regulation of glia during CNS injury and disease,” Nat Rev Neurosci, 21: 139-152 (2020).
[cited by applicant]
Grenier et al., “Three-dimensional modeling of human neurodegeneration: brain organoids coming of age,” Mol Psychiatry, 25: 254-274 (2020).
[cited by applicant]
Griffin, “What causes Alzheimer's?” The Scientist, 25:36-40 (2011).
[cited by applicant]
Grundman et al., “Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials,” Arch. Neurol. (2004) 61(1): 59-66.
[cited by applicant]
Guchardi et al., “Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations,” International Journal of Pharmaceutics 348:10-17 (2008).
[cited by applicant]
Gudesblatt et al., “Hexosaminidase A activity and amyotrophic lateral sclerosis,” Muscle and Nerve, II: 227-230 (1988).
[cited by applicant]
Guo et al., “Comparison of Delivery Characteristics from a Combination Metered-Dose Inhaler Using the Andersen Cascade Impactor and the Next Generation Pharmaceutical Impactor,” J Pharm Sci, 97(8): 3321-3334 (2008).
[cited by applicant]
Guo, J. et al., “Evaluating the levels of CSF and serum factors in ALS,”
[cited by applicant]
Gwin et al., “Cromolyn sodium in the treatment of asthma associated with aspirin hypersensitivity and nasal polyps,” Chest, 72(2):148-153 (1977).
[cited by applicant]
Haass et al., “Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid [beta]-peptide,” Nat Rev Mol Cell Biol, 8(2):101-112 (2007).
[cited by applicant]
Hallenbeck, J.M. “The many faces of tumor necrosis factor in stroke”. Nat Med (2002) 8, 1363-1368.
[cited by applicant]
Han et al., “The therapeutic effects of sodium cromoglycate against influenza A virus H5N1 in mice,” Influenza and Other Respiratory Viruses, 10(1): 57-66 (2015).
[cited by applicant]
Hashimoto et al., “Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide,” J Neurosci, 32(43):15181-15192 (2012).
[cited by applicant]
He et al., “Progress of Inhaled Devices for Asthma,” Journal of Applied Clinical Pediatrics, 22(4):309-311 (2007).
[cited by applicant]
Hemonnot et al., “Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities,” Front Aging Neurosci, 11:233(20 pages) (2019).
[cited by applicant]
Heneka et al., “Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV7171 transgenic mice,” Brain, 128:1442-1453 (2005).
[cited by applicant]
Hensley, “Neuroinflammation in Alzheimer's Disease: Mechanisms, Pathologic Consequences, and Potential for Therapeutic Manipulation,” J Alzheimers Dis, 21(1):1-14 (2010).
[cited by applicant]
Hirouchi, “Current status and perspectives on the development of therapeutic agents for Alzheimer's disease,” Nihon Yakurigaku Zasshi, 123(6):421-427 (2004).
[cited by applicant]
Holian et al., “Mechanistic aspects of cromolyn sodium action on the alveolar macrophage: inhibition of stimulation by soluble agonists,” Agents Actions, 33: 318-325 (1991).
[cited by applicant]
Hoozemans et al., “Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology,” CNS Neurol Disord Drug Targets, 10(1):57-67 (2011).
[cited by applicant]
Hopperton et al., “Markers of microglia in post-mortem brain samples from patients with Alzheimer's disease: a systematic review,” Mol Psychiatry, 23: 177-198 (2018).
[cited by applicant]
Hori et al., “A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid beta in the brain in a transgenic model of Alzheimer disease,” J Biol Chem, 290(4): 1966-1978 (2015).
[cited by applicant]
Hu et al., “Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study,” Scientific Reports, 7: Article No. 9094 (2017).
[cited by applicant]
Huang et al., “Acute stress induces cardiac mast cell activation and histamine release, effects that are increased in Apolipoprotein E knockout mice.,” Cardiovasc Res, 55(1):150-160 (2002).
[cited by applicant]
Huang et al., “Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice,” Cardiovasc Res, 59(1):241-249 (2003).
[cited by applicant]
Ihle-Hansen, H. et al., “Incidence and subtypes of MCI and dementia 1 year after first-ever stroke in patients without pre-existing cognitive impairment,”
[cited by applicant]
Ilieva, H., et al., “Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond,”
[cited by applicant]
Imbimbo et al., “Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?,” Front Aging Neurosci, 2(19):1-14 (2010).
[cited by applicant]
Imbimbo, “An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease,” Expert Opinion on Investigational Drugs, 2009; 18(8), pp. 1147-1168.
[cited by applicant]
InnoPharmalabs, “Particle Size Distribution”, Apr. 9, 2013 (Apr. 9, 2013).
[cited by applicant]
Intal Approval Package, Center for Drug Evaluation and Research, application 75-175, pp. 1-5 (Dec. 12, 1997).
[cited by applicant]
Intal® Nebulizer Solution (Label 2016): Retrieved online at <http://labeling.pfizer.com/ShowLabeling.aspx?id=833>: 4 pages (2016).
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2019/040247 dated Jan. 14, 2021.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US16/63143 mailed Feb. 6, 2017.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US16/63462 mailed Feb. 1, 2017.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US17/65727 mailed Feb. 12, 2018.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US19/49733 dated Jan. 13, 2020.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2010/022495 dated Nov. 10, 2010.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2014/061694 dated Jan. 2, 2015.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/049702 dated Dec. 26, 2017.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/026521 dated Jun. 14, 2019.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/040247 dated Sep. 20, 2019.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/025746 mailed Jun. 17, 2021.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/035936 dated Jul. 22, 2021.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/065200 dated Mar. 24, 2022.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US19/65384 dated Mar. 31, 2020.
[cited by applicant]
International Search Report for International Application No. PCT/US2013/066069 mailed Mar. 13, 2014.
[cited by applicant]
International Search Report for International Application No. PCT/US14/39118 dated Sep. 18, 2014.
[cited by applicant]
Jellinger, K.A., “Alzheimer disease and cerebrovascular pathology: an update”.
[cited by applicant]
Jin et al., “Mast cells are early responders after hypoxia-ischemia in immature rat brain,” Stroke, 40(9):3107-3112 (2009).
[cited by applicant]
Jin, R. et al., “Inflammatory mechanisms in ischemic stroke: role of inflammatory cells,”
[cited by applicant]
Jin, Y. et al., “Mast cell stabilization limits hypoxic-ischemic brain damage in the immature rat”.
[cited by applicant]
Jurga et al., “Overview of General and Discriminating Markers of Differential Microglia Phenotypes,” Front Cell Neurosci, 14: 198 (18 pages) (2020).
[cited by applicant]
Kamiya., “Characteristics and problems of cascade impactors in the evaluation of inhaled preparations,” Journal of Pharmaceutical Science and Technology, Japan, 65(4): English Machine Translation (5 pages)(2005).
[cited by applicant]
Karadsheh, “Rapid response to: Covid-19: what treatments are being investigated?” BMJ (4 pages) (2020).
[cited by applicant]
Karran et al., “The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics,” Nat Rev, 10(9):698-712 (2011).
[cited by applicant]
Kaur et al., “Drug Therapy in Stroke: From Preclinical to Clinical Studies,” Pharmacology, 92:324-334 (2013).
[cited by applicant]
Kay et al., “Disodium cromoglycate inhibits activation of human inflammatory cells in vitro,” J Allergy Clin Immunol, 80(1): 1-8 (1987).
[cited by applicant]
Keizman D. et al. Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis.
[cited by applicant]
Keller et al., “Have inadequate delivery systems hampered the clinical success of inhaled disodium cromoglycate? Time for reconsideration,” Exp Opin Drug Deliv, 8(1):1-17 (2011).
[cited by applicant]
Kelley et al., “The molecular role of mast cells in atherosclerotic cardiovascular disease,” Mol Med Today, 6:304-308 (2000).
[cited by applicant]
Kilpatrick et al., “Cromolyn inhibits assembly of the NADPH oxidase and superoxide anion generation by human neutrophils,”
[cited by applicant]
Knowles, “Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes,” Core Evid, 1(3):195-219 (2006).
[cited by applicant]
Kohman et al., “Neurogenesis, inflammation and behavior,” Brain Behav Immun, 27C:22-32 (2013).
[cited by applicant]
Kondo et al., “iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid β Combination for Alzheimer's Disease,” Cell Rep, 21: 2304-2312 (2017).
[cited by applicant]
Koo et al., “Amyloid diseases: Abnormal protein aggregation in neurodegeneration, ” PNAS, 96:9989-9990 (1999).
[cited by applicant]
Kotilinek et al., “Cyclooxygenase-2 inhibition improves amyloid-β-mediated suppression of memory and synaptic plasticity,” Brain, 131(3):651-664 (2008).
[cited by applicant]
Koudstaal et al., “Secondary Stroke Prevention in Atrial Fibrillation: Indications, Risks, and Benefits,” J Thromb Thrombolys, 7(1):61-65 (1999).
[cited by applicant]
Krstic et al., “Deciphering the mechanism underlying late-onset Alzheimer disease,” Nat Rev Neurol, 9:25-34(2013).
[cited by applicant]
Krueger, M. et al., “Blood-brain barrier breakdown involves four distinct stages of vascular damage in various models of experimental focal cerebral ischemia,”
[cited by applicant]
Kuhle, J. et al., Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis,
[cited by applicant]
Kumon et al., “Application and Mechanism of Inhalation Profile Improvement of DPI Formulations by Mechanofusion with Magnesium Stearate,” Chemical and Pharmaceutical Bulletin, 56(5): 617-625 (2008).
[cited by applicant]
Kwong et al., “Comparison of Nebulized Particle Size Distribution with Malvern Laser Diffraction Analyzer Versus Andersen Cascade Impactor and Low-Flow Marple Personal Cascade Impactor,” J Aerosol Med, 13(4): 303-314 (2…
[cited by applicant]
Lalancette-Hébert, M. et al., “Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain,”
[cited by applicant]
Lanari, et al., “Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting,” Scientific World Journal. (2009) 9: 961-6.
[cited by applicant]
Lanz et al., “The y-Secretase Inhibitor N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl Ester Reduces Aβ Levels in Vivo in Plasma and Cerebrospinal Fluid in Young (Plaque-Free) and Aged (Plaque-Bearing) …
[cited by applicant]
Lasiene, J and Yamanaka, K., “Glial cells in amyotrophic lateral sclerosis,”
[cited by applicant]
Lee, P.H. et al., “Circulating beta amyloid protein is elevated in patients with acute ischemic stroke”.
[cited by applicant]
Lehman, L.L. and Rivkin, M.J., “Perinatal arterial ischemic stroke: Presentation, risk factors, evaluation, and outcome”.
[cited by applicant]
Lewis et al., “Quantification of Alzheimer pathology in aging and dementia: age-related accumulation of amyloid-β (42) peptide in vascular dementia,” Neuropathology and Applied Neurobiology, 32(2): 103-118 (2006).
[cited by applicant]
Li et al., “TREM2 regulates innate immunity in Alzheimer's disease,” J Neuroinflammation, 15: 107 (7 pages) (2018).
[cited by applicant]
Libby, “Inflammation in atherosclerosis,” Nature, 420(6917):868-874 (2002).
[cited by applicant]
Lim et al., “Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model of Alzheimer's Disease,” The Journal of Neuroscience 20(15):5709-5714 (2000).
[cited by applicant]
Cited By (1)